FATTY ACID OVEREXPOSURE IS TOXIC to lean tissues and is likely implicated in the development of several chronic pathophysiological states, including insulin resistance and type 2 diabetes (8) . The current view is that accumulation of fatty acid metabolites such as long-chain acyl-CoA, phosphatidic acid, diacylglycerols, ceramides, and/or mitochondrial fatty acid overload from an imbalance between increased lean tissue fatty acid uptake and/or synthesis and reduced catabolism may lead to lipotoxicity and type 2 diabetes (9, 18, 24, 34) . Thus, quantification of all sources of tissue fatty acid overexposure, including that coming directly from dietary intake, would be essential to understand the causes of lipotoxic tissue injury in pathological conditions. Methods using stable isotopic or radioactive fatty acid tracers have been used for noninvasive quantification of dietary fatty acid absorption and whole body oxidation (28, 30, 35) or even organ-specific nonoxidative disposal of dietary fatty acids in combination with magnetic resonance spectroscopy (29) . To date, however, no method is available for noninvasive quantification of tissue partition and net uptake of dietary fatty acids in humans.
We have recently used the positron-emitting long-chain fatty acid analog 14(R,S)- [ 18 F]fluoro-6-thia-heptadecanoic acid ( 18 FTHA) administered by gavage to demonstrate increased myocardial dietary fatty acid uptake in diabetic rats using tissue extracts (23) . Here we describe a novel method designed to quantify dietary fatty acid tissue uptake and partition in healthy humans using 18 FTHA administered orally with sequential positron emission tomography coupled to computed tomography (PET/CT) scanning. We hypothesized that 18 FTHA administered orally during a meal would be incorporated into chylomicron triglycerides (TG) and, from there, be delivered to the different organs, allowing determination of interorgan dietary fatty acid uptake and partition using PET/CT imaging. We opted for 18 FTHA because its total tissue uptake is quantitatively similar to that of palmitate, a long-chain fatty acid clearly involved in lipotoxic processes leading to insulin resistance and type 2 diabetes.
METHODS
Ethical approval. Informed written consent was obtained from all participants in accordance with the Declaration of Helsinki, and the protocol received approval from the Human Ethics Committee of the Centre Hospitalier Universitaire de Sherbrooke. All animal protocols were approved by the Animal Ethics Committee of the Faculty of Medicine at the University of Sherbrooke in accordance with the guidelines of the Canadian Council on Animal Care.
Human subjects and animals. Nine healthy men between ages 18 and 60 without first-degree family history of type 2 diabetes and with normal glucose tolerance based on a 75-g oral glucose tolerance test participated in this metabolic study. None of the participants had a current medical condition or were taking drugs known to affect lipid levels or insulin sensitivity. Fourteen male Wistar rats (Charles River Laboratories) weighing 400 -450 g and acclimatized to a 12:12-h day-light cycle at a constant temperature (22°C) for 7 days were used for the animal experiments.
Human experimental protocols. The subjects were instructed to follow an isocaloric diet (0% alcohol, 15% protein, 30% fat, and 55% carbohydrates) 48 h before the experimental protocol. On arrival, body weight, height, and waist circumference were measured, and lean body mass was determined by electrical bioimpedance (Hydra ECF/ICF; Xitron Technologies, San Diego, CA). An intravenous catheter was placed in one forearm for infusions, and another was placed in a retrograde fashion in the contralateral arm maintained in a heating pad (ϳ55°C) for blood sampling.
The metabolic protocol is depicted in Fig. 1A . Oral intake of a standard liquid meal consisted of a drink prepared by sonication of soybean oil (54 g/l), safflower oil (54 g/l), dried non-fat milk (263 g/l), egg phospholipids (0.18 g/l), and water with the addition of chocolate syrup (202 g/l) and sugar (15 g/l) to provide 2,465 kcal/l, 39% as fat, 16% as proteins, and 45% as carbohydrates (27) . Its fatty acid composition was similar to the composition of Intralipid, an intravenous fat emulsion that we have used in previous studies (4, 6) . The oral intake of the drink corresponded to 80 ml every 5 min over 20 min for a total of 1,680 kcal.
Each participant underwent a PET/CT protocol that consisted of a 6-h postprandial procedure. Each subject was positioned supine in a 16-slice PET/CT scanner (Philips Gemini GXL; Philips, Eindhoven, The Netherlands) using a row action maximum likelihood algorithm without sinogram rebinning for reconstructing images. The other parameters were as follows: isotropic voxel size of 4 mm, 60 cm in diameter by 18 cm axial field of view. Whole body CT scans (16 mAs) were performed to correct for attenuation and for definition of PET regions of interests. At time 0 min, ϳ70 MBq 18 FTHA produced as described previously (10) was mixed into Intralipid 20% (Baxter, Mississauga, ON, Canada), incorporated into gel capsules (TUB Enterprises), and given orally. In five subjects, [ 3 H]triolein (ϳ300 Ci) was sonicated into the liquid meal. Total radioactivity exposure to the participants was Ͻ8 mSv. The maximal gastrointestinal tract exposure for oral 18 FTHA administration was estimated at 2.35 mSv in the stomach. All tracers were pretested for sterility and nonpyrogenicity, and their use in humans was approved by Health Canada and the Human Ethics Committee of the Centre Hospitalier Universitaire de Sherbrooke.
The protocols started with 30-min bed rest, after which blood samples were taken at 30-min intervals for the duration of the experiment. Blood was collected in tubes containing Na 2EDTA and Orlistat (30 g/ml; Roche, Mississauga, ON, Canada) to prevent in vitro triglyceride lipolysis. A first set of dynamic PET scanning was performed during the last 30-min of 1st hour to determine whether 18 FTHA is absorbed directly into the portal circulation and accumulates early in the liver. A second set of dynamic PET acquisition was performed during the last 30 min of the 2nd hour to image 18 FTHA delivery into the thoracic duct. At times 60, 120, 180, 240, 300, and 360 min, whole body PET/CT acquisitions were performed to determine 18 FTHA tissue distribution and uptake. Animal experimental protocols. After a 12-h fasting period, animals were anesthetized with isoflurane (Abott Laboratories, Montreal, QC, Canada) delivered through a nose cone at a concentration of 2.0% (vol/vol). Anesthesia was maintained for all duration of in vivo experiments (Fig. 1B) . A catheter was placed into a carotid artery for blood sampling.
At time 0 min, ϳ30 MBq of 18 FTHA produced as described previously (10) and 10 Ci [ 3 H]triolein were mixed into 0.7 ml of Intralipid 20% and were given orally using a gavage syringe. Immediately before gavage, Triton WR-1339 (400 mg/kg, referred to as TRI group, Tylaxapol; Sigma Chemical) vs. normal saline (referred to as SAL group) was injected intravenously to inhibit intravascular TG lipolysis during the experiment (7, 22) . This technique allowed us to determine that most 18 FTHA administered orally in rats indeed reached the circulation as TG. All in vivo experiments described herein were initiated 30 min after insertion of a catheter, after which blood samples were taken at 15-min intervals during the 2-h postprandial procedures. Blood was collected in tubes containing Na 2EDTA and Orlistat (30 g/ml; Roche) to prevent in vitro TG lipolysis.
PET/CT image analysis. For dynamic PET acquisition, mean value of pixels [mean standard uptake value (SUV)] for each frame were recorded. Regions of interest (ROI) were drawn on the liver (hepatic dynamic) and thoracic duct (thoracic duct dynamic) to generate tissue time-radioactivity curves. The regions of interest were first defined from the transaxial CT slices and then copied to 18 FTHA image sequences. For whole body scans, mean value of pixels (mean SUV) for all tissues of interest were recorded. ROI were drawn on the liver, heart, quadriceps femoris, thigh subcutaneous adipose tissue, and right perirenal adipose tissue (a visceral adipose tissue depot; this depot was chosen to avoid gut spillover of 18 F activity that occurred in most other splanchnic adipose tissue depots).
18 FTHA metabolite analysis. Human plasma metabolite was determined using a solid-phase extraction method. Briefly, Oasis MAX 6-ml (500 mg) LP Extraction Cartridges (no. 186000865; Waters) were activated with 6 ml of acetonitrile (ACN), 6 ml of methanol (MeOH), and 6 ml of 2% ammonium hydroxide (NH 4OH-H2O). One milliliter of plasma was mixed with 9 ml of a solution of 2% NH4OH-10% MeOH-H2O. This solution was applied to the cartridge, and the liquid phase that contains TG was pulled through and collected. The column was washed first with 10 ml of 2% NH 4OH- Data are means Ϯ SE. BMI, body mass index; NEFA, nonesterified fatty acids; TG, triglycerides. 70% CAN-MeOH to remove the remaining TGs, which were collected in the same tube. The column was then eluted with 10 ml of 5% formic acid-70% CAN-MeOH to collect nonesterified fatty acids (NEFA) into another tube. TG and NEFA samples were transferred into a counting ␥-tube to measure 18 For animal studies, plasma metabolite samples were precipitated with methanol and centrifuged, and the supernatant fraction that contained circulating lipids was separated onto thin-layer chromatography C-18 reverse-phase plates (RP-18 F-254; Merck, Darmstadt, Germany) to determine the fraction of 18 FTHA in circulating NEFA, TG, and phospholipids. The plates were eluted in a methanol-wateracetic acid (85:15:0.4) solution and read using Instant Imager (Version 1.27; Packard Instruments). Then, plates were stained with dichlorofluorocein (1 mg/ml ethanol) and revealed with UV detection.
Chylomicron separation. Chylomicrons were separated in QuickSeal centrifuge tubes (no. 344619; Beckman) from 1 ml of plasma overlaid with 4.5 ml of distilled water centrifuged for 15 min at 33,000 rpm at 20°C (Optima L-100XP ultracentrifuge with a 100Ti Beckman rotor). After centrifugation, the chylomicron fraction at the top of the tube was removed (ϳ800 l) and transferred into the counting ␥-tube to measure 18 F activity. Other laboratory assays. Glucose, insulin, total NEFA, and TGs were measured as described previously (6, 23) .
Statistical analyses. Data are expressed as means Ϯ SE. An unpaired Student's t-test was used to compare characteristics between SAL and TRI groups. ANOVA for repeated measurements with time as the independent variable was used to analyze differences in plasma glucose, insulin, NEFA, and TGs throughout the protocol. ANOVA for repeated measurements with tissue or organ as the independent variable was used to analyze differences in 18 FTHA tissue or organ biodistribution. A two-tailed P value Ͻ0.05 was considered significant. All analyses were performed with the SAS software for Windows version 9.1.3 (SAS Institute, Cary, NC) or GraphPad Prism for Windows version 5.00 (GraphPad, San Diego, CA).
RESULTS

Characteristics of human subjects and animals.
The characteristics of the human participants and animals, including fasting plasma metabolite and hormone concentrations, are shown in Tables 1 and 2 , respectively. In animals, there was no difference in these parameters between the SAL and TRI groups. During the postprandial procedure in humans, we observed the expected increases in plasma glucose and insulin, with peaks at 60 ( Fig. 2A ) and 90 min (Fig. 2B) , respectively. Plasma NEFA levels (Fig. 2C) decreased rapidly, reaching nadir at time 120 min, with a progressive increase thereafter up to the end of the postprandial protocol at 360 min. Total plasma TGs increased progressively, reaching a peak at time 330 min of the postprandial procedure (Fig. 2D) .
Determination of absorption route of orally administered 18 FTHA in humans. To ascertain that uptake into the circulation of orally administered 18 FTHA does not occur through This scanning shows no early portal and significant liver 18 FTHA uptake up to 60 min after meal consumption. C: PET dynamic acquisition of the thoracic duct. This scanning shows early and gradual apparition of 18 FTHA in the thoracic duct reflecting tracer incorporation into chylomicrons for delivery into the circulation in the subclavicular vein. direct uptake into the portal circulation and is transported to the circulation through the thoracic duct, we performed dynamic acquisition of the liver and portal vein between time 30 and 60 min and of the thorax with the distal thoracic duct between time 90 and 120 min after meal ingestion. There was no detectable 18 FTHA activity in the portal vein or significant liver accumulation of the tracer Յ60 min after meal intake despite the presence of a significant amount of the tracer in the duodenum (Fig. 3B) . However, we found early appearance of 18 FTHA activity in the distal thoracic duct and joining the subclavicular vein (Fig. 3C) (7) or saline (SAL group) as control. As shown in Fig. 5, A and B , TRI animals displayed significant and similar increases of 18 F and 3 H in plasma and significant increases in plasma TG levels (Fig. 5C) . At time 120 min after gavage, 92% of plasma 18 F was recuperated in TG in the TRI group compared with 17% in SAL animals, suggesting that almost all 18 FTHA administered orally initially reached the circulation as TG in rats (Fig. 5D) .
Uptake and partition of orally administered 18 FTHA in tissues after meal ingestion. To demonstrate uptake and partition of 18 FTHA in organs and tissues, we performed whole body PET/CT scanning every hour after meal ingestion. As shown in Fig. 6A , we observed progressive uptake of 18 FTHA in tissues and in the thoracic duct (shown by arrows). Figure 6 , B and C, shows mean SUV of ROI over time. 18 F mean SUV increased progressively in the distal thoracic duct, liver, heart, quadriceps femoris, and thigh subcutaneous adipose tissue up to time 240 min and up to time 180 min in visceral adipose tissues (right perirenal fat). The mean slope of 18 F SUV increase was 0.67 Ϯ 0.07, 0.31 Ϯ 0.04, 0.06 Ϯ 0.01, 0.03 Ϯ 0.01, and 0.17 Ϯ 0.04 mean SUV/h in the liver, heart, quadriceps femoris, thigh subcutaneous, and perirenal adipose tissues, respectively (P Ͻ 0.05 for difference between all organs except between quadriceps femoris and thigh subcutaneous adipose tissue). Figure 7 shows relative orally administered 18 FTHA uptake as assessed by area under the mean SUV curve over 6 h in the liver, heart, quadriceps femoris, thigh subcutaneous, and right perirenal adipose tissue (13.37 Ϯ 0.37, 6.24 Ϯ 0.36, 0.98 Ϯ 0.19, 0.61 Ϯ 0.05, and 3.73 Ϯ 0.59, respectively; P Ͻ 0.05 between all organs and tissues).
DISCUSSION
Many investigators have used stable or long-life radioactive isotopic tracer methods to determine chylomicron metabolism in circulation and dietary fatty acid absorption, partition into circulating lipoproteins, uptake into subcutaneous adipose tissues and skeletal muscle, and whole body oxidation (1-3, 16, 28, 30, 35) . 13 C-labeled fatty acids administered orally have also been used to detect postprandial uptake of dietary fatty acids in skeletal muscle and liver in humans by magnetic resonance spectroscopy (29) . However, the latter method can only determine tracer accumulation into nonoxidative metabolic pathways and does not have the sensitivity to determine Fig. 6 . Organ and tissue distribution of orally administered 18 FTHA in humans. A: Gemini GXL PET whole body acquisition 1-6 h following oral administration of 18 FTHA in a healthy subject showing progressive uptake of 18 FTHA in tissues and in the thoracic duct (arrows). B: mean standard uptake value (SUV) of the distal thoracic duct (dark red circles and dark red line), liver (brown squares and brown line), heart (red triangles and red line), quadriceps femoris (green triangles and green line), thigh subcutaneous adipose tissue (orange diamonds and orange line), and right perirenal adipose tissue (dark orange circles and dark orange line) over time is shown. Very high mean SUV in the distal thoracic duct that peaked at 4 h demonstrates 18 FTHA incorporation into chylomicrons entering the systemic circulation through the left subclavicular vein. C: the lower graph shows natural logarithmic transformation for better resolution of muscle and subcutaneous adipose tissue uptake.
dietary fatty acid tracer uptake in most internal organs, such as, for example, the heart. To our knowledge, this is the first study to report a method that can quantify dietary fatty acid absorption and assembly into chylomicron, their delivery into the thoracic duct, and their simultaneous distribution and uptake into all tissues and organs in humans. Although it has been possible in some instances to use an arteriovenous gradient even across the heart or liver circulation or visceral adipose tissue biopsies during abdominal surgery to determine circulating TG and/or NEFA metabolism in these internal organs in humans (16, 21, 25, 26) , these studies are very invasive and difficult to perform, making assessment of organ-specific metabolism of dietary fatty acids impossible in most situations. In addition, it has previously been impossible to simultaneously measure partition of dietary fatty acids in all internal organs in humans, a major advantage of the novel method described herein. Others have previously used 123 I-heptadecanoic acid administered orally to perform imaging of the thoracic duct with planar scintigraphy, but without CT anatomic and spatial resolution of the collimation their method was poor, and tissue uptake was confounded by a high rate of free 123 I recirculation and uptake (14) . 18 FTHA administered intravenously was shown to be an excellent noninvasive method to quantify organ-specific NEFA uptake in the heart, skeletal muscles, liver, and adipose tissues (10 -12, 15, 19, 23, 33) . The thiol residue at position 6 leads to trapping into mitochondria due to blockade of its ␤-oxidation after the first two iterations of 18 F positioned downstream of the carbon chain. This property of the tracer allows quantification of tissue 18 FTHA uptake by linearization methods, such as the Patlak method, for the determination of tissue uptake of plasma NEFA (19, 23, 33 ). In the context of oral administration, the very slow oxidative degradation of 18 FTHA also allows detection of progressive tissue accumulation of the tracer delivered by chylomicrons, a process that is too slow to accurately detect with other PET fatty acid tracers such as [ 11 C]palmitate. NEFA fractional tissue uptake determined with 18 FTHA was shown to be similar to that reported for [ 11 C]palmitate (17, 33) . We found that total 18 FTHA uptake in tissue lipids is similar to that of [ 3 H]palmitate and that 18 FTHA mitochondrial uptake is similar to that of [ 14 C]bromopalmitate (10) . These studies thus suggest that 18 FTHA initial transport into cells and mitochondria is similar to that of endogenous long-chain fatty acids. We and others, however, have found relatively less 18 FTHA esterification into tissue TG associated with reciprocal increase into tissue diacylglycerols and/or phospholipids (10, 32) . Thus, 18 FTHA tissue nonoxidative metabolism is qualitatively but not quantitatively different from endogenous fatty acids. One caveat, however, is that tissue 18 FTHA accumulation may be less sensitive to differences in the final esterification step of diacylglycerol molecules into TG. However, it is interesting to note that almost all of the incorporation of 18 FTHA into chylomicrons in humans as well as in rats in the present work occurred into TGs. Whether this may limit inference with regard to oral 18 FTHA uptake in tissues such as adipose tissue that display relatively high fatty acid esterification into TG will need more investigation. All this evidence suggests that 18 FTHA administered orally is a reasonably good tracer of net dietary fatty acid tissue uptake but cannot distinguish dietary fatty acid oxidation and nonoxidative metabolism.
The bulk of dietary long-chain fatty acids absorbed by the intestine undergo esterification and assembly into chylomicrons in enterocytes (20) . Chylomicrons are then secreted and transported in the splanchnic lymphatic circulation to the thoracic duct and reach the circulation in the left subclavicular vein. Although short-and medium-chain fatty acids may be absorbed and transported directly into the portal circulation for efficient oxidative metabolism in the liver (31, 36, 37) , this process is probably very limited for long-chain fatty acids, except perhaps in conditions associated with portal hypertension (5). The present study clearly demonstrates very poor direct absorption of 18 FTHA into the portal circulation and preferential uptake and secretion into chylomicrons. Despite the relative inefficient 18 FTHA esterification into tissue TG (10, 32), we found remarkably similar rates of incorporation of orally administered 18 FTHA and [ 3 H]triolein into plasma and chylomicron TG. Our findings in rats using Triton WR-1339 also strongly support preferential delivery of orally administered 18 FTHA as TG in the circulation. Whole body PET/CT determination of orally administered 18 FTHA tissue uptake demonstrated that the highest uptake of dietary fatty acids per gram of tissue occurs in the liver in humans. This finding is consistent with the known preferential liver uptake of intravenously administered fatty acid tracers in animals (10) . It is also consistent with the higher NEFA spillover rate from circulating TG in the splanchnic vs. systemic circulation in humans (25) and with hepatic uptake of chylomicron remnants (13) . The relatively high cardiac dietary fatty acid uptake that we observed is also consistent with significant myocardial uptake of circulating TG in humans (26) . The relatively high visceral adipose tissue (as assessed by uptake into right perirenal adipose tissue depot) vs. subcutaneous adipose tissue dietary fatty acid uptake that we observed was also expected on the basis of previous studies using radioactive tracers prior to adipose tissue biopsies during abdominal surgery in humans (16) .
Our novel method has some limitations. First, as mentioned above, this method cannot make the distinction between oxidative vs. nonoxidative tissue dietary fatty acid metabolism. Second, it assumes that local tissue hydrolysis of 18 FTHA esterified into chylomicron TG occurs at rate similar to longchain dietary fatty acids. Third, although tissue 18 FTHA clearance is very slow and probably negligible in most tissues over a few hours time frame (10), 18 FTHA likely redistributes into VLDL-TG for secretion, thus leading to underestimation of liver uptake from tracer accumulation in that tissue over time. Likewise, it is possible that some of the 18 FTHA uptake early in the postprandial period in adipose tissues may be released later into circulation, as suggested by the small reduction in 18 F adipose tissue activity observed after 3-4 h (see Fig. 5 ). Fourth, high gastrointestinal 18 F activity prevents accurate measurement of dietary fatty acid uptake in most visceral adipose tissue depots because of spillover of radioactivity. Fifth, thoracic duct SUV was likely underestimated due to partial volume effect since its expected diameter is at the limit of resolution of the PET scanner. However, this actually supports our conclusion that 18 FTHA incorporates first into chylomicrons and gets access to other organs through the thoracic duct because thoracic duct SUV was higher than in other organs despite this underestimation. Finally, to limit radioactivity exposure, we had to reduce whole body CT intensity that resulted in inadequate image qualities for accurate integration of the volume of most tissues. However, accurate measurement of organ volumes will be possible in future studies using magnetic resonance imaging or higher intensity CT scanning targeted at a specific organ of interest.
Because of the qualitative differences in 18 FTHA esterification into TGs, it is possible that 18 FTHA oral administration may underestimate tissue dietary lipid uptake from tracer recirculation into VLDL-TG late in the postprandial state. In the n ϭ 1 human study, we have isolated VLDLs and nevertheless found increased tracer uptake into the total VLDL fraction 5 and 6 h after 18 FTHA oral administration. This investigation was very difficult to perform and limited because of the low radioactivity signal left after the time required for the VLDL isolation procedure (in addition to time delay in vivo). Furthermore, we have documented 18 FTHA incorporation into VLDL-TG using plasma lipid separation by thin-layer chromatography after intravenous injection of 18 FTHA in both humans and animals (see, for example, Ref. 10). We invariably find progressive increases of 18 F signal into plasma TG 10 -15 min after 18 FTHA intravenous injection. Therefore, there is evidence that 18 FTHA can recirculate into VLDL-TG, but whether tissue uptake of 18 FTHA from VLDL is similar to that of endogenous fatty acids remains to be determined.
In conclusion, our findings suggest that orally administered 18 FTHA with PET/CT scanning is a good tracer for noninvasive determination of dietary fatty acid absorption, secretion into chylomicrons, and organ-specific uptake in humans. This novel method will be invaluable for the investigation of conditions associated with disordered dietary fatty acid organ partition and metabolism. 
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